Eventide Healthcare & Life Sciences is a good option in the biotechnology fund niche for investors who understand the substantial risks. It just hired its third comanager in less than three years, but lead manager Finny Kurivilla has remained a constant. The strategy maintains ratings of Above Average for People and Average for Process.
Eventide Healthcare & Life Sciences N ETNHX
- NAV / 1-Day Return 34.99 / +0.63 %
- Total Assets 1.5 Bil
-
Adj. Expense Ratio
1.510%
- Expense Ratio 1.510%
- Distribution Fee Level Above Average
- Share Class Type No Load
- Category Health
- Investment Style Small Growth
- Min. Initial Investment 1,000
- Status Open
- TTM Yield 0.00
- Turnover 71%
USD | NAV as of Oct 04, 2024 | 1-Day Return as of Oct 04, 2024, 10:28 PM GMT+0
Morningstar’s Analysis ETNHX
Will ETNHX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 33.2
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Mirum Pharmaceuticals Inc | 4.36 | 62.8 Mil | Healthcare |
Celldex Therapeutics Inc | 4.01 | 57.8 Mil | Healthcare |
Vaxcyte Inc Ordinary Shares | 3.87 | 55.8 Mil | Healthcare |
Lexeo Therapeutics Inc | 3.75 | 54.0 Mil | Healthcare |
Insmed Inc | 3.14 | 45.2 Mil | Healthcare |
Aura Biosciences Inc | 3.04 | 43.9 Mil | Healthcare |
Guardant Health Inc | 2.91 | 41.9 Mil | Healthcare |
Collegium Pharmaceutical Inc | 2.87 | 41.4 Mil | Healthcare |
Axsome Therapeutics Inc | 2.78 | 40.0 Mil | Healthcare |
Sarepta Therapeutics Inc | 2.51 | 36.1 Mil | Healthcare |
United States